Encapsulated Cell Technology Delivering Ciliary Neurotrophic Factor for Early-Stage Retinitis Pigmentosa: Neurotech


Trial Status: Phase II/III completed; planning next clinical trial.

Description: Neurotech conducted and completed a 30-month Phase II/III clinical trial of its Encapsulated Cell Technology (ECT) — a tiny capsule implanted into the — for the treatment of early-stage retinitis pigmentosa, Usher syndrome (types 2 and 3), and choroideremia. The ECT contains retinal pigment epithelial cells which provide sustained delivery of ciliary neurotrophic factor, a vision-preserving protein, to the retina. Two different doses of the treatment were evaluated. The Foundation funded the clinical trial as well as preclinical research that made the trial possible. Neurotech reported that the retinas of treated eyes were thicker than those untreated, indicating that the therapy was possibly having a positive biological effect. No improvement in vision was reported. Approximately 60 people were enrolled in the multicenter study.

Neurotech Treatment Shows Biological Effect in RP Clinical Studies

Additional Information:
Neurotech early-stage clinical trial listing on ClinicalTrials.gov